Ebos at Point Where 'Investor Confidence Can Start to Rebuild'
Dow Jones
Aug 20
0453 GMT - Ebos's FY 2026 result was notable partly because of what it didn't include. "With the lack of another EPS downgrade, we are hopeful this result has marked the end of Ebos's downgrade cycle and investor confidence can start to rebuild," says Forsyth Barr analyst Ben Crozier. Still, Ebos hasn't delivered a return to its historic growth rate of 5%. Forsyth Barr estimates Ebos's organic growth rate in FY 2026 was 2%, largely reflecting competitive headwinds in its Community Pharmacy business. Forsyth Barr retains a neutral call on Ebos.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.